Lisa Fichtel, MD
Medical Oncology · San Antonio, TXNPI 1932122348
Payments from drug & device makers
Across 62 payments — averaging $40.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AbbVie$467
- Pfizer$132
- AstraZeneca$129
- E.r. Squibb & Sons, L.L.C.$106
- Bristol Myers Squibb$95
- plus $461 from 14 others
What the payments were for
- Food & beverage$98347%
- Education$975%
- Other$99748%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $1,113 |
| AbbVie | 4 | $467 |
| Pfizer | 5 | $132 |
| AstraZeneca | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Bristol Myers Squibb | 4 | $95 |
| Astellas Pharma US Inc | 3 | $64 |
| Taiho Oncology, Inc. | 2 | $60 |
| Puma Biotechnology, Inc. | 3 | $59 |
| Genentech USA, Inc. | 3 | $48 |
| Gilead | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Genmab U.S., Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Fennec Pharmaceuticals, Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Bayer | 1 | $15 |
How this compares
$2,503 in reported general payments places this provider in the 25th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 40 | $7,137 |
| Anastrozole | 183 | $2,422 |
| Dexamethasone | 35 | $988 |
| Tamoxifen Citrate | 15 | $496 |
| Letrozole | 30 | $484 |
| Gabapentin | 32 | $277 |
| Ondansetron OdtOndansetron | 41 | $248 |
| Ondansetron Hcl | 27 | $195 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $171 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Antonio
- Amita PatnaikSan Antonio$17.8M
- Anthony TolcherSan Antonio$15.9M
- Sukeshi AroraSan Antonio$9.1M
- John SarantopoulosSan Antonio$9M
- Virginia KaklamaniSan Antonio$5.5M
- Lei ZhengSan Antonio$5.3M
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.